All News
ACR25 - Day 1 Report
ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content.
Read Article
@RheumNow on Social Media:
✧ virtual learning is the future of medicine
✧use digital strategies to filter good data online- AI can help focus interests & stay up to date - ex. Consensus or Feedly!
✧ peer to peer learning through social media enhances learning
#ACR25 https://t.co/n6MzhYoz0n
Kailey Singh doctorkails ( View Tweet)
ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences.
@RheumNow #ACR25 A#1042
Jiha Lee JihaRheum ( View Tweet)
#1077 More health literacy work from our group!
995 people with inflammatory arthritis: lower health literacy linked to higher absenteeism & presenteeism
Those with highest HLQ scores were mostly retired with better engagement in care
@RheumNow #ACR25
Come check out our poster! https://t.co/CaqzkjMWYB
Mrinalini Dey DrMiniDey ( View Tweet)
In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon.
I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out:
https://t.co/Zq4ywEjspi https://t.co/3RYCVunE3a
Links:
David Liew drdavidliew ( View Tweet)
@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology:
- bias at scale
- erosion of skills
- data regulatory issues
(for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better)
@RheumNow https://t.co/FyNes40Z7q
David Liew drdavidliew ( View Tweet)
In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way):
guardrails - they need to happen
@RheumNow https://t.co/ccLLC3adxG
Links:
David Liew drdavidliew ( View Tweet)
#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭
Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/xn4yUta9Da
Dr. John Cush RheumNow ( View Tweet)
Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be residual confounders based on impact of adjustments however... @RheumNow #ACR25 Abstr#1340 https://t.co/cd0JLW8nGD
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
Links:
sheila RHEUMarampa ( View Tweet)
Social media based outreach to pts for research
Out of 617,207 users engaged, 6 filled the contact form
Based on this social media (knowing also promotion costs) might not be the best strategy to recruit for clinical trials
@RheumNow #ACR25 https://t.co/qCH9WXyTD7
Aurelie Najm AurelieRheumo ( View Tweet)
Where do patients find informations about their RMD?
Study of 705pts
-80% search engines via smartphone 80.3%
Different pattern within 2 yrs of diagnosis vs. later stage:
-more frequent 19% vs 8%
Most users find online content -understandable 80%
-apply it in daily life 68% https://t.co/9IMvpt2ffr
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Rheumatologists love AI scribes in clinic.
The way we interact is potentially well suited, and accuracy and synthesis quality is bound to improve. Is it inevitable that it will universally be standard practice for us soon?
UCSF clinics #ACR25 @JYazdanyMD ABST0189 @RheumNow https://t.co/kOzfpLlvgD
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Two Jacks, One mission 🤓
Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!)
Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5
sheila RHEUMarampa ( View Tweet)
Why do pts with #Still’s #AOSD
Get hospitalized?
#Sepsis
1827 unweighted & 9135 Weighted #US #hospitalizations
Worse in
men
Black
Medicaid
But is it truly #infection or Still’s flare or both?
Abst#0163
ACR25 @RheumNow @rheumacr
#ACRBest as largest N ever! https://t.co/fLMNyQQNNj
Janet Pope Janetbirdope ( View Tweet)
Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Real-world JAK persistence in RA is low: <30% at 2 years across Medicare & Marketscan data (n≈20K). Baricitinib lowest persistence; TOF & UPA slightly higher. Oral convenience hasn’t solved long-term adherence. Why? Safety, cost, access?
@RheumNow #ACR25 A#0369
Jiha Lee JihaRheum ( View Tweet)
